Recent Updates
Recently added Catalysts
RCEL Positive Sentiment Score: 70/100

AVITA Medical to Host Investor Webinar Briefing

Key Takeaway: AVITA Medical, a leader in therapeutic acute wound care, is set to host an investor webinar on February 18, 2025. The event will feature CEO Jim Corbett and CFO David O'Toole discussing financial results from Q4 and full-year 2024. Participants can also engage in a Q&A following the presentation. The RECELL System, a key technology of AVITA, is utilized in skin healing and has received multiple international approvals.

Market Sentiment Analysis

POSITIVE FACTORS

  • AVITA Medical is hosting a webinar that may engage investors.
  • The presentation includes important financial and business results.
  • RECELL System is approved and recognized for its effectiveness in wound care.

Full Press Release Details

VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The webinar presentation will cover financial and business results from our recent fourth quarter and full-year 2024 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
To register for the presentation, please follow this Zoom link:
A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering a groundbreaking solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit  www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Tags

Frequently Asked Questions

When is the AVITA Medical investor webinar?

The investor webinar is on February 18, 2025, at 2:00 p.m. PST.

Who will present at the AVITA Medical webinar?

Jim Corbett and David O’Toole will present at the webinar.

How can I register for the AVITA Medical presentation?

You can register using the provided Zoom link in the announcement.

What will be discussed in the webinar?

The webinar will cover AVITA Medical’s financial results and include a Q&A.

Where can I find the webinar replay?

The replay will be available on the AVITA Medical website after the webinar.

Last updated: Feb 14, 2025